Browsing by Author "Antunes de Melo Oliveira, Ana Mafalda"
Now showing items 1-20 of 24
-
BEECH: a dose-finding run-in followed by a randomised phase II study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with estrogen receptor-positive advanced or metastatic breast cancer, and in a PIK3CA mutant sub-population
Turner, N. C.; Alarcón, E.; Armstrong, A. C.; Philco, M.; López Chuken, Y. A.; Sablin, Marie-Paule; Antunes de Melo Oliveira, Ana Mafalda (Oxford University Press, 2019-05-01) -
Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer
Bardia, Aditya; Tolaney, Sara M; Punie, Kevin; Loirat, Delphine; Antunes de Melo Oliveira, Ana Mafalda; Kalinsky, K. (Elsevier, 2021-09) -
Biomarker Analysis of the Phase III NALA Study of Neratinib + Capecitabine versus Lapatinib + Capecitabine in Patients with Previously Treated Metastatic Breast Cancer
Matito Ariza, Judit; Antunes de Melo Oliveira, Ana Mafalda; Wildiers, Hans; Brufksy, Adam M.; Waters, Simon; Vivancos Prellezo, Ana; Saura Manich, Cristina (American Association for Cancer Research, 2021-11-01) -
Brain Metastases in HER2-Positive Breast Cancer: Current and Novel Treatment Strategies
Garcia-Alvarez, Alejandro; Papakonstantinou, Andri; Antunes de Melo Oliveira, Ana Mafalda (MDPI, 2021-06) -
Efficacy of Neratinib Plus Capecitabine in the Subgroup of Patients with Central Nervous System Involvement from the NALA Trial
Hurvitz, Sara; Antunes de Melo Oliveira, Ana Mafalda; Trudeau, Maureen E.; Moy, Beverly; Delaloge, Suzette; Saura Manich, Cristina (Wiley, 2021-08) -
Evolving Landscape of Molecular Prescreening Strategies for Oncology Early Clinical Trials
Garralda Cabanas, Elena; Aguilar, Susana; Sala De Vedruna, Gemma; Viaplana Donato, Cristina; González-Zorelle, Jenifer; Grazia LoGiacco, Deborah; Ogbah, Zighereda; Mancuso, Francesco Mattia; Fasani, Roberta; Jiménez Flores, José Antonio; Martinez, Paola; Oaknin Benzaquen, Ana Mazaltob; Antunes de Melo Oliveira, Ana Mafalda; Balmaña Gelpí, Judith; Carles Galceran, Joan; Macarulla Mercadé, Teresa; Elez Fernandez, Mª Elena; Alsina Maqueda, Maria; Braña Garcia, Irene; Felip Font, Enriqueta; Tabernero Caturla, Josep; Rodon Ahnert, Jordi; Nuciforo, Paolo Giovanni; Vivancos Prellezo, Ana; Ramos Masdeu, Laia; Saura Manich, Cristina; Ruiz Pace, Fiorella; Dienstmann, Rodrigo (American Society of Clinical Oncology, 2020-05-14) -
First Nationwide Molecular Screening Program in Spain for Patients With Advanced Breast Cancer: Results From the AGATA SOLTI-1301 Study
Pernas, Sonia; Villagrasa, Patricia; Vivancos Prellezo, Ana; Scaltriti, Maurizio; Rodon Ahnert, Jordi; Burgués, Octavio; Nuciforo, Paolo Giovanni; Antunes de Melo Oliveira, Ana Mafalda (Frontiers Media, 2021-11-04) -
Functional Mapping of AKT Signaling and Biomarkers of Response from the FAIRLANE Trial of Neoadjuvant Ipatasertib plus Paclitaxel for Triple-Negative Breast Cancer
Shi, Zhen; Wulfkuhle, Julia; Nowicka, Malgorzata; Gallagher, Rosa Isela; Nuciforo, Paolo Giovanni; Antunes de Melo Oliveira, Ana Mafalda; Saura Manich, Cristina (American Association for Cancer Research, 2022-03-01) -
Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative
Antunes de Melo Oliveira, Ana Mafalda; Irrthum, Alexandre; Fumagalli, Debora; Sotiriou, Christos; Gal-Yam, Einav Nili; Aftimos, Philippe (American Association for Cancer Research, 2021-11) -
Health-related quality of life in the phase III ASCENT trial of sacituzumab govitecan versus standard chemotherapy in metastatic triple-negative breast cancer
Loibl, Sibylle; Loirat, Delphine; Tolaney, Sara M; Punie, Kevin; Antunes de Melo Oliveira, Ana Mafalda; Rugo, Hope (Elsevier, 2023-01) -
High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer
Palafox Sánchez, Marta; Monserrat Vicente, Laia; Gonzalez-Perez, Abel; Antunes de Melo Oliveira, Ana Mafalda; Òdena, Andreu; Sanchez-Guixe, Monica; Capelan Rodríguez, Marta; Azaro Pedrazzoli, Analía Beatriz; Rodriguez Ferreiro, Olga; Guzman Torres, Marta; Grueso Gragera, Judit; Viaplana Donato, Cristina; Hernandez Losa, Javier; Arribas López, Joaquin Vicente; Nuciforo, Paolo Giovanni; Serra Elizalde, Violeta; Villacampa Javierre, Guillermo; Bellet Ezquerra, Meritxell; Saura Manich, Cristina; Dienstmann, Rodrigo (Nature Portfolio, 2022-09-07) -
Immune microenvironment characterisation and dynamics during anti-HER2-based neoadjuvant treatment in HER2-positive breast cancer
Griguolo, Gaia; Pascual, Tomás; Fasani, Roberta; Chic, N.; Antunes de Melo Oliveira, Ana Mafalda; Nuciforo, Paolo Giovanni; Serna, Garazi; Guardia, Xavier (Nature Research, 2021-03-19) -
Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial
Lin, Nancy U.; Borges, Virginia; Murthy, Rashmi K.; Paplomata, Elisavet; Hamilton, Erika; Antunes de Melo Oliveira, Ana Mafalda; Anders, Carey (American Society of Clinical Oncology, 2020-08-10) -
Ipatasertib plus paclitaxel for PIK3CA/AKT1/PTEN-altered hormone receptor-positive HER2-negative advanced breast cancer: primary results from cohort B of the IPATunity130 randomized phase 3 trial
Dent, Rebecca; O’Shaughnessy, Joyce; Kim, Sung‑Bae; Isakoff, S. J.; Barrios, Carlos; Antunes de Melo Oliveira, Ana Mafalda; Turner, Nicholas (Springer, 2022-02) -
Metabolic Imaging Detects Resistance to PI3Kα Inhibition Mediated by Persistent FOXM1 Expression in ER+ Breast Cancer
Ros, Susana; Wright, Alan J.; D’Santos, Paula; Hu, De-en; Hesketh, Richard L.; Lubling, Yaniv; Antunes de Melo Oliveira, Ana Mafalda (Cell Press, 2020-10-12) -
Neoadjuvant eribulin in HER2-negative early-stage breast cancer (SOLTI-1007-NeoEribulin): a multicenter, two-cohort, non-randomized phase II trial
Pascual, Tomás; Antunes de Melo Oliveira, Ana Mafalda; Villagrasa, Patricia; Ortega Cebrian, Vanesa; Bermejo, Begoña; Nuciforo, Paolo Giovanni; Rubio Rodríguez, Isabel Teresa; Cortés Castan, Javier; Paré, Laia (Nature Research, 2021-11-25) -
Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial
Antunes de Melo Oliveira, Ana Mafalda; Feng, Yin-Hsun; Dai, Ming-Shen; Chen, Shang-Wen; Hurvitz, Sara; Saura Manich, Cristina (American Society of Clinical Oncology, 2020-09-20) -
Neratinib + capecitabine sustains health-related quality of life in patients with HER2-positive metastatic breast cancer and ≥ 2 prior HER2-directed regimens
Moy, Beverly; Antunes de Melo Oliveira, Ana Mafalda; Gradishar, William; Kim, Sung‑Bae; Brufsky, Adam; Saura Manich, Cristina (Oxford University Press, 2021-07) -
Next Generation-Targeted Amplicon Sequencing (NG-TAS): an optimised protocol and computational pipeline for cost-effective profiling of circulating tumour DNA
Gao, Meiling; Callari, Maurizio; Beddowes, Emma; Sammut, Stephen-John; Grzelak, Marta; Biggs, Heather; Cortés Castan, Javier; Antunes de Melo Oliveira, Ana Mafalda (BMC, 2019-01-04) -
Palbociclib combined with endocrine therapy in heavily pretreated HR + /HER2 - advanced breast cancer patients: Results from the compassionate use program in Spain (PALBOCOMP)
Manso, Luis; Hernando, Cristina; Galán, María; Antunes de Melo Oliveira, Ana Mafalda; Cabrera, Miguel A.; Bratos, Raquel (Elsevier, 2020-12-01)